Insights On CONTRACT PHARMA MANUFACTURING

31. Minimizing Risk In RNA-LNP Encapsulation And Drug Product Manufacturing 3/31/2025

    Learn about an integrated drug substance/drug product offering for your IND program and beyond, with a holistic approach to ensure process robustness at every stage.

32. The 5 Ws Of A Human Factors Strategy 3/31/2025

    A human factors strategy ensures medical products are safe, effective, and compliant by integrating user-focused design early, reducing risks, and optimizing regulatory approval processes.

33. The Relevance Of Polymorph Screening In The Pharmaceutical Industry 3/31/2025

    Polymorph screening identifies different solid forms of active pharmaceutical ingredients, optimizing drug stability, solubility, and manufacturability. This process ensures quality, regulatory compliance, and intellectual property protection in pharmaceutical development.

34. Oncology Solutions: Accelerate Your Cancer Therapeutics Development 3/27/2025

    Join the global effort to advance cancer research and contribute to the development of personalized treatments that target the unique characteristics of each patient's disease.

35. Overcoming Barriers To Membrane Technology: Demonstrating Protein A Affinity Capture Quality, Process Similarity 3/25/2025

    Explore how the interchangeable use of Protein A membrane and resin media can streamline your bioprocessing workflows, ensuring efficient, scalable, and high-quality manufacturing from lab scale to full-scale production.

36. Shear and Flow In High-Productivity Membrane Affinity Chromatography 3/25/2025

    Explore how understanding hydrodynamic shear, turbulent flow, and interface-induced aggregation can optimize your protein purification process and improve protein stability in high-productivity membrane chromatography systems.

37. 10 Minutes On Optimizing Upstream Process Development 3/25/2025

    Gain insight into how UPD ensures scalable and compliant processes, facilitates the efficient development of innovative therapeutics, and contributes to molecule development and production.

38. From Bench To 20k L Bioreactor: Optimizing Cell Culture Scale-Up 3/25/2025

    Master scale-up strategies, optimize key parameters, and ensure a seamless transition from bench to large-scale bioreactors for a thriving biopharmaceutical process.

39. GMP-Focused Platform Processes For Microbial, pDNA, And mRNA 3/25/2025

    Mario Kraft, Director of Process Development at AGC Biologics' Heidelberg facility, explains how platform processes optimize microbial, plasmid DNA, and mRNA production.

40. A Friendly CDMO Expert: New CEO Outlines AGC Bio's Transformation 3/25/2025

    Experience a friendlier, more reliable approach to biopharmaceutical manufacturing with AGC Biologics, your trusted partner for minimizing risks and fostering collaboration.